Ultragenyx Pharmaceutical (RARE) News Today $37.35 +1.16 (+3.21%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RARE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Millennium Management LLC Sells 13,453 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Millennium Management LLC reduced its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 1.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 697,236 shares of the biopharmaceutical company's stock after selling 1May 21 at 4:54 AM | marketbeat.comSherbrooke Park Advisers LLC Acquires Shares of 10,387 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Sherbrooke Park Advisers LLC acquired a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,387 shares of the bioMay 20 at 5:47 AM | marketbeat.comMan Group plc Trims Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Man Group plc cut its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 9.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 297,394 shares of the biopharmaceutical company'sMay 20 at 5:20 AM | marketbeat.comAnalysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Target Price at $90.93May 19 at 3:09 AM | americanbankingnews.comSphera Funds Management LTD. Has $9.63 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Sphera Funds Management LTD. increased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 17.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 228,776 shares of the biopharmaceutical company's stock afterMay 18 at 6:55 AM | marketbeat.comPoint72 Asset Management L.P. Grows Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Point72 Asset Management L.P. raised its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 81.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,182,877 shares of the biopharmaceutical coMay 18 at 6:15 AM | marketbeat.comPoint72 Hong Kong Ltd Grows Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Point72 Hong Kong Ltd grew its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 173.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,399 shares of the biopharmaceuticalMay 18 at 6:08 AM | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by MPM Bioimpact LLCMPM Bioimpact LLC boosted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 18.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 391,018 shares of the biopharmaceuticaMay 16, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $4.21 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Parkman Healthcare Partners LLC reduced its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 8.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 100,159 shares of the biopharmaceuMay 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 51.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owneMay 16, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have been given an average rating of "Moderate Buy" by the fifteen analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and fourteen have issuedMay 16, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $12.04 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)D. E. Shaw & Co. Inc. grew its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 9.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 286,079 shares of the biopharmMay 16, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc.: Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact ReportMay 15, 2025 | finanznachrichten.deBNP Paribas Financial Markets Buys 113,797 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)BNP Paribas Financial Markets grew its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 394.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 142,628 shares of the biopharmaceutMay 15, 2025 | marketbeat.comNorthern Trust Corp Purchases 55,641 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Northern Trust Corp increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 11.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 528,965 shares of the biopharmaceutical company's stock after buying an additional 5May 15, 2025 | marketbeat.comUltragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact ReportMay 14, 2025 | globenewswire.comHudson Bay Capital Management LP Buys 182,500 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Hudson Bay Capital Management LP raised its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 93.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 377,500 shares of the biopharmaMay 13, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Lifted by Graham Capital Management L.P.Graham Capital Management L.P. grew its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 37.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 59,129 shares of the bMay 13, 2025 | marketbeat.comWedbush Issues Pessimistic Estimate for RARE EarningsUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Stock analysts at Wedbush lowered their Q2 2025 earnings estimates for Ultragenyx Pharmaceutical in a research report issued on Wednesday, May 7th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnMay 13, 2025 | marketbeat.comWedbush Expects Lower Earnings for Ultragenyx PharmaceuticalMay 13, 2025 | americanbankingnews.comLeerink Partnrs Has Bullish Outlook for RARE Q2 EarningsUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Leerink Partnrs boosted their Q2 2025 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a report released on Wednesday, May 7th. Leerink Partnrs analyst J. Schwartz now anticipates that the biopharmaceutical company wiMay 11, 2025 | marketbeat.comFred Alger Management LLC Sells 70,033 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Fred Alger Management LLC decreased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 13.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 466,2May 11, 2025 | marketbeat.comDZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Raises Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 17.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 346,597 sMay 11, 2025 | marketbeat.comDriehaus Capital Management LLC Has $34.90 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Driehaus Capital Management LLC lifted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 5.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 829,465 sharesMay 11, 2025 | marketbeat.com27,949 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Bought by Crestline Management LPCrestline Management LP acquired a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 27,949 shares of thMay 11, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This YearMay 9, 2025 | finance.yahoo.comDeep Track Capital LP Buys Shares of 653,513 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Deep Track Capital LP purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 653,513 shares of the biopharmaceutical company's stock, valued at approMay 9, 2025 | marketbeat.comBrevan Howard Capital Management LP Has $1.48 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Brevan Howard Capital Management LP grew its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 116.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,201 shares of the biopharmaceutical company's stockMay 9, 2025 | marketbeat.comAlgert Global LLC Purchases 8,891 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Algert Global LLC boosted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 12.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 82,793 shares of the biopharmaceutical company's stock aftMay 9, 2025 | marketbeat.comCutter Capital Management LP Has $17.11 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Cutter Capital Management LP raised its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 41.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 406,803 shares of the biopharmaceutical company's stock after buyMay 8, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Lowered by Bamco Inc. NYBamco Inc. NY reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 16.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,000 shares of the biopharmaceutical company's stock aftMay 8, 2025 | marketbeat.comAQR Capital Management LLC Trims Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)AQR Capital Management LLC reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 73.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 280,547 shares of the biopharmaceutical company's stock after sMay 8, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Sells 21,468 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)The Manufacturers Life Insurance Company trimmed its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 9.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 216,587 shares of theMay 8, 2025 | marketbeat.comRaymond James Financial Inc. Buys New Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Raymond James Financial Inc. bought a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 21,774 shares of the biopharmaceutical company's stoMay 8, 2025 | marketbeat.comQ1 2025 Ultragenyx Pharmaceutical Inc Earnings CallMay 7, 2025 | finance.yahoo.comUltragenyx to Participate at Bank of America’s 2025 Healthcare ConferenceMay 7, 2025 | uk.finance.yahoo.comUltragenyx Pharmaceutical's Earnings: A PreviewMay 7, 2025 | nasdaq.comUltragenyx to Participate at Bank of America's 2025 Healthcare ConferenceMay 7, 2025 | globenewswire.comAxa S.A. Boosts Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Axa S.A. increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 7.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 456,588 shares of the biopharmaceutical company's stock after purchasing an aMay 7, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comUltragenyx misses Q1 estimates, shares fall on weak resultsMay 6, 2025 | investing.comUltragenyx Reports First Quarter 2025 Financial Results and Corporate UpdateMay 6, 2025 | globenewswire.comAvidity Partners Management LP Has $14.81 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Avidity Partners Management LP lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 53.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 352,000 shares of the biopharmaceutical compaMay 6, 2025 | marketbeat.comAlyeska Investment Group L.P. Increases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Alyeska Investment Group L.P. boosted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 23.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,439,740 shares of the biopharmaceMay 6, 2025 | marketbeat.comInsider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Sells 520 Shares of StockMay 6, 2025 | insidertrades.comShort Interest in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Grows By 20.5%Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 5,460,000 shares, a growth of 20.5% from the March 31st total of 4,530,000 shares. Based on an average trading volume of 824,100 shares, the short-interest ratio is presently 6.6 days. Currently, 6.3% of the company's shares are short sold.May 5, 2025 | marketbeat.comAlkeon Capital Management LLC Has $70.96 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Alkeon Capital Management LLC lowered its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 44.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,686,716 shares of the biopharmaceutical company's stocMay 5, 2025 | marketbeat.comVoya Investment Management LLC Sells 89,772 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Voya Investment Management LLC trimmed its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 55.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 72,321 shares of the biopharmaceutical company's stock after sellingMay 5, 2025 | marketbeat.comHsbc Holdings PLC Purchases 31,416 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Hsbc Holdings PLC increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 195.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 47,516 shares of the biopharmaceutical company's stock after acquiring an additional 3May 4, 2025 | marketbeat.comPDT Partners LLC Sells 17,334 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)PDT Partners LLC lessened its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 26.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,859 shares of the biopharmaceutical company's stock after selliMay 2, 2025 | marketbeat.com Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Media Mentions By Week RARE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RARE News Sentiment▼1.120.65▲Average Medical News Sentiment RARE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RARE Articles This Week▼168▲RARE Articles Average Week Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genmab A/S News Dr. Reddy's Laboratories News Viatris News Moderna News Ascendis Pharma A/S News Qiagen News Roivant Sciences News Revolution Medicines News Elanco Animal Health News Blueprint Medicines News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RARE) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
